Table 4.
Tumor Immune Biomarker sTILs and PD-L1 with 22C3 antibody (N = 20).
| Patient ID | Best Response | Tissue | % sTILs | PD-L1 |
|---|---|---|---|---|
| COH-01 | PD | NA | NA | NA |
| COH-02 | PD | NA | NA | NA |
| COH-03 | SD | NA | NA | NA |
| COH-04 | PD | Skin | 5% | Neg |
| COH-05 | PD | Liver | 10 | 1% |
| COH-06 | SD | Breast | 5% | Neg |
| COH-07 | PD | Frontal tumor | NA | Neg |
| COH-08 | PR | Breast | NA | Neg |
| COH-09 | PD | Liver | NA | NA |
| COH-10 | PR | Supraclavicular mass | 5% | Neg |
| COH-11 | PD | Liver | 5% | Neg |
| COH-12 | PD | Bone | NA | Neg |
| COH-13 | SD | Chest wall | 10% | 50% |
| COH-14 | PD | Axillary LN | 70% | NA |
| COH-15 | PD | Ovary | NA | 2% |
| COH-16 | PD | Skin | 2% | Neg |
| COH-17 | PD | LN | NA | NA |
| COH-18 | PD | Liver | NA | Neg |
| COH-19 | PD | Chest wall | 10% | Neg |
| COH-20 | PD | Liver | NA | Neg |
sTILs, stromal tumor infiltrating lymphocytes; PR, partial response; SD, stable disease; PD, progression of disease; NA, not applicable; LN, lymph node; Pos, positive; Neg, negative.